<DOC>
	<DOCNO>NCT02129595</DOCNO>
	<brief_summary>The main objective study investigate resveratrol supplementation improve overall muscle-specific insulin sensitivity first-degree relative type 2 diabetic patient . As secondary objective investigator want investigate whether improved insulin sensitivity attribute improved muscle mitochondrial oxidative capacity reduce intrahepatic cardiac lipid content . Furthermore , subset participant investigator want investigate effect resveratrol glucose uptake brown adipose tissue .</brief_summary>
	<brief_title>Resveratrol First-degree Relatives Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<mesh_term>Antineoplastic Agents , Phytogenic</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Peripheral Nervous System Agents</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Male sex Age : 4070 year BMI 2735 kg/m2 Has firstdegree relative ( ) diagnose type 2 diabetes Sedentary Not 2 hour sport week No active job require strenuous physical activity Stable dietary habit : weight gain loss &gt; 5kg last three month Insulin resistant : glucose clearance rate &lt; 350 ml/kg/min , determine use OGIS120 Willingness abstain resveratrolcontaining food product Subjects include dependent medical doctor study approve participation evaluate data obtain screen Use anticoagulant Uncontrolled hypertension Haemoglobin &lt; 7.8 mmol/l In case abnormal ECG rest : discuss responsible medical doctor HBA1C &gt; 6.5 % Diagnosed type 2 diabetes Medication use know interfere glucose homeostasis/metabolism Current alcohol consumption &gt; 20 grams/day Subjects n't want inform unexpected medical finding screen /study , wish physician inform , participate study . Subjects intend donate blood intervention subject donate blood less three month start intervention . Participation another biomedical study within 1 month first screen visit Any condition , disease abnormal laboratory test result , opinion Investigator , would interfere study outcome , affect trial participation put subject undue risk Any contraindication MRI scanning . These contraindication include patient follow device : Central nervous system aneurysm clip Implanted neural stimulator Implanted cardiac pacemaker defibrillator Cochlear implant Insulin pump Metal contain corpus aliena eye brain</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Resveratrol</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Hyperinsulinism</keyword>
	<keyword>Anti-Inflammatory Agents , Non-Steroidal</keyword>
	<keyword>Analgesics , Non-Narcotic</keyword>
	<keyword>Analgesics</keyword>
	<keyword>Sensory System Agents</keyword>
	<keyword>Peripheral Nervous System Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Antineoplastic Agents , Phytogenic</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Antioxidants</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Protective Agents</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Antimutagenic Agents</keyword>
	<keyword>Anticarcinogenic Agents</keyword>
	<keyword>Central Nervous System Agents</keyword>
	<keyword>Brown Adipose Tissue</keyword>
</DOC>